Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 279

1.

Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.

Lim YC, Desta Z, Flockhart DA, Skaar TC.

Cancer Chemother Pharmacol. 2005 May;55(5):471-8. Epub 2005 Feb 1.

PMID:
15685451
2.

Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells.

Lim YC, Li L, Desta Z, Zhao Q, Rae JM, Flockhart DA, Skaar TC.

J Pharmacol Exp Ther. 2006 Aug;318(2):503-12. Epub 2006 May 11.

3.

Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation.

Zheng Y, Sun D, Sharma AK, Chen G, Amin S, Lazarus P.

Drug Metab Dispos. 2007 Oct;35(10):1942-8. Epub 2007 Jul 9.

4.

Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.

Chang HL, Sugimoto Y, Liu S, Ye W, Wang LS, Huang YW, Lin YC.

Anticancer Res. 2006 May-Jun;26(3A):1773-84.

5.

Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen.

Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA, Skaar TC.

Breast Cancer Res Treat. 2004 May;85(2):151-9.

6.

Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer.

Lu WJ, Desta Z, Flockhart DA.

Breast Cancer Res Treat. 2012 Jan;131(2):473-81. doi: 10.1007/s10549-011-1428-z. Epub 2011 Mar 9.

PMID:
21390495
7.

Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines.

Vendrell JA, Bieche I, Desmetz C, Badia E, Tozlu S, Nguyen C, Nicolas JC, Lidereau R, Cohen PA.

Endocr Relat Cancer. 2005 Mar;12(1):75-92.

8.

Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases.

Sun D, Sharma AK, Dellinger RW, Blevins-Primeau AS, Balliet RM, Chen G, Boyiri T, Amin S, Lazarus P.

Drug Metab Dispos. 2007 Nov;35(11):2006-14. Epub 2007 Jul 30.

9.

The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.

Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC.

Cancer Res. 2009 Mar 1;69(5):1722-7. doi: 10.1158/0008-5472.CAN-08-3933. Epub 2009 Feb 24.

10.

mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen.

Revillion F, Pawlowski V, Lhotellier V, Louchez MM, Peyrat JP.

Anticancer Res. 2003 Mar-Apr;23(2B):1455-60.

PMID:
12820409
11.

Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score.

Barginear MF, Jaremko M, Peter I, Yu C, Kasai Y, Kemeny M, Raptis G, Desnick RJ.

Clin Pharmacol Ther. 2011 Oct;90(4):605-11. doi: 10.1038/clpt.2011.153. Epub 2011 Sep 7.

PMID:
21900890
12.

A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen.

Balkenende EM, Dahhan T, Linn SC, Jager NG, Beijnen JH, Goddijn M.

Hum Reprod. 2013 Apr;28(4):953-9. doi: 10.1093/humrep/des445. Epub 2013 Jan 18.

PMID:
23335608
13.

Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites.

Wolf DM, Langan-Fahey SM, Parker CJ, McCague R, Jordan VC.

J Natl Cancer Inst. 1993 May 19;85(10):806-12.

PMID:
8487325
14.

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA.

J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64.

PMID:
14652237
15.

An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4'-hydroxylated metabolites in breast cancer patients.

Dahmane E, Mercier T, Zanolari B, Cruchon S, Guignard N, Buclin T, Leyvraz S, Zaman K, Csajka C, Decosterd LA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Dec 15;878(32):3402-14. doi: 10.1016/j.jchromb.2010.10.027. Epub 2010 Oct 30.

PMID:
21094101
16.

Tamoxifen metabolite isomer separation and quantification by liquid chromatography-tandem mass spectrometry.

Jaremko M, Kasai Y, Barginear MF, Raptis G, Desnick RJ, Yu C.

Anal Chem. 2010 Dec 15;82(24):10186-93. doi: 10.1021/ac102337d. Epub 2010 Nov 18.

PMID:
21086978
17.

[Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines].

Bachmann-Moisson N, Barberi-Heyob M, Merlin JL, Ledrich ML, Batt AM, Guillemin F.

Bull Cancer. 1996 Oct;83(10):808-15. Review. French.

PMID:
8952630
18.
19.
20.

Supplemental Content

Support Center